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Abstract 
Potentially malignant disorders are recognisable mucosal conditions preceding 
invasive squamous carcinoma development. Established oral cancer remains a 
lethal and deforming disease, with a rising incidence. Management techniques for 
identifiable oral precursor lesions have traditionally been polarised between 
observational and interventional surgical techniques. By defining salient 
management goals for treating potentially malignant disease, and examining the 
evidence supporting the efficacy of treatment intervention, this paper presents the 
case for interventional laser surgery as a definitive diagnostic and treatment 
modality.   
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Introduction 
Potentially malignant disorders (PMD) are recognisable oral mucosal lesions, 
primarily leukoplakia, but also erythroleukoplakia, erythroplakia and proliferative 
verrucous leukoplakia (PVL), which precede in an unpredictable manner invasive 
squamous cell carcinoma (SCC) development1,2. Whilst variable malignant 
transformation rates have been quoted, a systematic review estimated an overall 
12% cancer risk over a mean transformation time of 4.3 years3.  
The ensuing morbidity and high mortality consequent upon SCC diagnosis and 
treatment remains significant in contemporary clinical practice and, whilst the 
objectives of treating PMD have been poorly defined, most authorities agree that 
prevention of malignancy is the priority4. This is complicated, however, by the 
widespread, often multi-focal nature of disease throughout the upper aerodigestive 
tract1.  
We have previously defined salient management goals supporting an interventional 
strategy for PMD management, as outlined in Table 1, and also published a series of 
long-term patient cohort studies demonstrating the efficacy of intra-oral CO2 laser 
surgical excision, both as an accurate diagnostic tool and a reliable treatment 
modality particularly for managing ‘high-risk’ PMD4-8. Following initial 
histopathological diagnosis and risk assessment, mucosal lesions are excised by 
laser with margins ablated by vapourisation allowing healing by secondary intention5. 
Evidence from a 590 PMD cohort confirmed that interventional surgery provided 
definitive diagnosis and treatment, facilitated early SCC recognition, identified 
patients at risk of progressive disease, rationalised follow-up and helped define 
clinical outcome data8. 
In a recent journal editorial, however, Guneri & Epstein9 repeat a number of 
previously raised concerns regarding the use of surgical intervention in PMD 
management. Whilst these are summarised in Table 2, of particular concern are the 
suggestions of ‘over-treatment’, ‘increased cost of care’ and the view that PMD 
excision ‘does not show benefit with respect to progression to cancer’.  
For many years, of course, PMD management was controversially polarised 
between surgical excision to remove identifiable mucosal disease and conservative 
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medical or observational techniques10. Shiu & Chen11 attempted a systematic review 
of treatment efficacy for leukoplakia, but found wide variation in diagnostic criteria, 
extensive heterogeneity of treatment protocols, disorganised patient compliance and 
incomplete follow-up data rendering meaningful analyses impossible.  
Review of non-surgical managements, including antioxidant and chemotherapeutic 
approaches, have shown no proven efficacy, demonstrated high risk for side effects, 
substantive recurrence following treatment cessation and, most pertinently, no 
evidence of cancer prevention10,12,13. One report observed an increased 31.4% 
malignant transformation rate in leukoplakia treated with isoretinoin and β-
carotene14, whilst other studies confirmed only 2 to 4% of clinicians would use 
chemo-preventive agents, emphasising the contemporary redundancy of this 
modality15,16.  
Whilst ‘potential malignancy’ is undoubtedly a difficult concept for both patients and 
clinicians, it intuitively warrants interventional management rather than passive 
observation17,18. van der Waal19, astutely noting that most PMD patients prefer 
treatment intervention, recommended surgical excision of localised lesions followed 
by long-term, specialist follow-up; a view supported by many clinicians20,21.  
The aim of this article, therefore, is to review contemporaneous literature regarding 
PMD treatment and, by addressing each of the stated PMD treatment goals, attempt 
to clarify the case for interventional surgical management. 
 
Accurate and Definitive Histo-Pathological Diagnosis 
Characteristic of PMD is the variable presence of epithelial disorganisation and 
dysmaturation, identified microscopically as dysplasia and graded subjectively for 
severity1,2. Although evidence remains weak, it is generally assumed that more 
severe dysplasia is at greatest risk of cancer development1,2. With no predictive 
biomarkers available, accurate histo-pathological diagnosis remains essential in 
clinical practice, yet incision biopsies are not necessarily representative of the true 
and evolving nature of PMD, particularly large and widespread disorders. A 
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significant ‘under-diagnosis ratio’, varying between 14 to 36%, is seen when incision 
specimens are compared with their excision counterparts22-25.  
Incision biopsy, therefore, can only be regarded as a ‘provisional’ diagnosis, with 
whole lesion excision deemed mandatory for ‘definitive’ PMD diagnosis and grading; 
the latter is facilitated by CO2 laser excision2,4,8,26. Whilst thermal cytological artefacts 
at excision margins have been suggested as a limitation of laser biopsy, these do not 
adversely affect histopathology assessment and reporting by experienced oral 
pathologists5-8. In addition, it is also recognised that the absence of dysplasia in 
incision biopsies does not rule out the risk of pre-existing or developing cancer in 
individual PMD lesions25,27. 
Multiple lesion disease, particularly widespread and pan-oral presentation which 
affects around 25% of PMD patients, is undoubtedly more challenging to manage but 
the technique of ‘field mapping’ whereby multiple-site incision biopsies are performed 
to delineate more significant foci of dysplastic disease facilitates pragmatic, targeted 
intervention to high-risk regions28,29. 
  
Prediction of Clinical Behaviour  
The ability to accurately predict clinical outcome for individual patients or lesions 
remains elusive in clinical practice4,5. However, long-term follow-up of defined PMD 
patient cohorts undergoing coordinated interventional treatment has facilitated 
documentation of clinical outcome and defined categories of disease free, further 
PMD disease, malignant (same-site) transformation and new-site oral cancer 
development4. Retrospective analyses have identified predictive features: disease 
free status is more likely in cases of mild dysplasia, but significantly less common 
with erthroleukoplakia and lesions exhibiting lichenoid inflammation, whilst further 
disease occurs more frequently in PVL and in the absence of laser excision8. The 
likelihood of SCC development is increased in erythroleukoplakia, in severe 
dysplasia and in lesions arising on the floor of mouth and ventro-lateral tongue8.    
As a general observation, the incidence of further disease increases with length of 
patient follow-up, with non-homogeneous leukoplakia, extensive lesions, more 
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severe dysplasia and floor of mouth and ventral tongue sites at greatest risk7. 
Continued tobacco smoking and alcohol remain persistent risk factors following laser 
surgery risking development of further PMD7,30.  
 
Early Recognition of Malignancy  
Sufficient evidence exists to confirm that PMD excision facilitates early recognition of 
cancer.  Review of surgically treated cases shows that ‘unexpected’ SCCs, often at 
early invasive stages, are identified histo-pathologically in 7 to 12% of excision 
specimens 8,23-25,31; a figure not dissimilar to the 12% transformation rate quoted in 
systematic review3 and an important diagnostic and treatment success. The efficacy 
of intervention is confirmed in our study cohorts because few patients required post-
laser oncology treatment and long-term follow-up revealed excellent clinical 
outcomes7,8,25.  
SCC detection at an early stage enables curative treatment with simple and minor 
surgical intervention4,32. In contrast, the limitations of PMD observation are 
highlighted by a 25% malignant transformation rate reported in a UK dysplasia clinic 
where there was no coordinated treatment protocol and SCC diagnoses only made 
following clinically evident malignant change32.   
 
Effective Removal of Premalignant Tissue 
As mucosal-only conditions, PMDs do not require the extensive treatment necessary 
for SCC removal or destruction. It seems self-evident to intervene early and remove 
dysplastic mucosa whilst ‘pre-invasive’. Surgery can be performed by scalpel, cutting 
diathermy or photodynamic therapy but the efficacy of dysplasia excision by CO2 
laser is confirmed in patient cohort studies5-8. Dysplasia-free margins or residual foci 
of mild dysplasia are seen in 75% of treated cases7,30, but with no significant 
association between dysplasia in resection margins and clinical outcome, almost 
certainly due to the ability to extend treatment zones by laser ablating oral cavity 
margins 2-4mm beyond specimen excision4. 
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Whilst minimal intervention has been proposed for less severely dysplastic lesions,   
treatment of all mucosal pre-malignancy is recommended to reduce risks of 
recurrence and disease progression consequent upon observing even mildly 
dysplastic lesions33,34. 
 
Prevention of Further Disease  
Well-defined clinical outcome categories are essential prerequisites to inform clinical 
practice and improve understanding of PMD natural history1,2.  Review of CO2 laser 
treatment studies shows that 51 to 89% of PMD patients are rendered free of 
disease, with only 10 to 34% exhibiting further disease8,35-40; this contrasts with 
observational treatment in which 77% of lesions persist41.    
Following successful primary therapy, local PMD recurrence and development of 
new-site lesions may occur42, but careful patient follow-up facilitates early 
identification and further laser treatment can be administered. Whilst most patients in 
our study series required only 1 laser treatment, a mean number of 2.26 treatments 
over a mean time of 32.9 months ultimately rendered over 74% of 590 PMD patients 
disease free despite initial presentation with significant dysplasia8.  
 
Prevention of Malignant Transformation 
It is a fundamental hypothesis, and the most significant justification for PMD 
intervention, that surgical removal of a dysplastic lesion will reduce the risk of 
malignant transformation. Studies have shown 15% transformation rates for patients 
whose lesions were not excised, compared with around 5-6% where lesions were 
removed3,43.  
Excluding SCCs excised ‘unexpectedly’, we have noted between 2 to 5% of PMD 
patients developing same or new-site cancer formation during post-treatment follow-
up5-8.  Local surgical excision of dysplastic lesions appears to decrease the risk of 
same-site malignant transformation, but does not eliminate the risk of new-site oral 
cancer development13,34,44. The clinical consequence is the realization that continued 
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patient surveillance, regular clinic monitoring and risk factor profiling remain pertinent 
for all PMD cases following treatment4.  
 
Patient Acceptability and Minimal Morbidity 
As CO2 laser surgery is recommended as the preferred PMD management choice, it 
is important that it is both acceptable to patients and post-operative morbidity is low. 
Significant complications following CO2 laser treatment are rare and, whilst some 
patients report post-operative pain, submandibular salivary gland swelling following 
floor of mouth procedures and lingual nerve dysaesthesia after tongue surgery, 
these are usually transient, self-limiting and rarely require additional treatment6,45.  A 
small number of patients report prolonged complications but these are usually after 
more extensive surgery, or in those who continue to smoke heavily or consume 
alcohol after treatment45.   
In general, laser surgery is well tolerated and accepted by patients, aids 
haemostasis, promotes excellent healing and produces minimal scarring with little 
functional deficit or patient morbidity5. A particular advantage is the ability to repeat 
excisions or ablations at the same site without compromising oral healing or 
function4,5. No significant adverse quality of life outcomes for PMD patients have 
been reported, particularly in contrast to the known physical and psycho-social 
consequences of SCC treatment46. 
Whilst no consensus exists to determine the nature or duration of PMD follow-up, a 
policy of active surveillance offers patients a number of additional treatment 
advantages and helps advance understanding of PMD natural history and disease 
progression5; Table 3. Interventional management should be considered cyclical in 
nature, passing from active surgical excision through to surveillance but returning to 
surgical intervention upon diagnosis of further disease. It is, therefore, a consistent 
and determined approach to patient management4,5.  
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Cost Effectiveness 
Few data exist in the literature to support or refute the concept that early, minimal 
intervention, essentially secondary or tertiary SCC prevention in ‘at risk’ populations, 
is cost-effective, but it is not an unreasonable hypothesis. Rather than increasing 
cost of care, targeted PMD excision is likely to prove less expensive than the 
alternative of multiple, repeat incision biopsies performed over many years of 
observational follow-up44. There may be additional cost savings in centralizing 
services for PMD patients within specialist oral oncology centres5.  
In considering wider aspects of health economics, it is necessary to balance PMD 
treatment efficacy, cost and value for money with anticipated costs of oncology 
treatment. Recently introduced UK Department of Health Patient-Level Information 
and Costing Systems (PLICS) allow estimates of costs incurred by NHS healthcare 
organizations providing specific treatments. PLICS data from the Newcastle upon 
Tyne Hospitals NHS Foundation Trust over 6 months (April-October 2015) 
contrasted diagnostic and surgical services for PMD laser surgery (averaged at 
around £997.90 per treated patient) with multi-disciplinary SCC care (£5,471.58 per 
patient). Initial SCC treatment cost more than 5 times PMD management, without 
considering the significant additional costs of head and neck cancer care, including 
adjuvant radiotherapy and/or chemotherapy treatments.   
 
Conclusions 
Clinical outcomes for oral cancer will only improve by earlier detection of SCC and 
effective management of precursor lesions with malignant potential47. The 
consequences for an individual patient progressing to SCC are devastating. There 
seems little to gain from observational strategies, particularly as substantive 
evidence, summarised in Table 4, supports the diagnostic and treatment efficacy of 
intervention as a definitive treatment modality. Interventional laser surgery provides 
readily available, effective, low morbidity treatment which is successful in excising 
PMD mucosal lesions, facilitates early diagnosis of occult SCC and may help reduce 
overall risk of SCC development.  
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In the future, PMD patients will require better stratification into ‘high’ and ‘low’ risk 
categories, with individually tailored treatment protocols based upon bio-molecular 
and genetic profiling of cancer risk. Whilst awaiting such refinements, and in the 
absence of meaningful multi-centre, prospective randomised trials, the contemporary 
case for interventional management is presented. 
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TABLE 1: MANAGEMENT GOALS IN TREATING PMD  
 
Management Goals 
Accurate Diagnosis 
Prediction of Clinical Behaviour 
Early Recognition of Malignancy 
Removal of Dysplastic Mucosa 
Prevention of Further Disease  
Prevent Malignant Transformation 
Patient Acceptability and Minimal  Morbidity 
Cost-Effective 
 
 
 
TABLE 2: PERCEIVED CRITICISM OF INTERVENTIONAL PMD TREATMENT 
 
Risk of ‘over-treatment’ of benign lesions unlikely to progress to cancer 
Cost of treatment  
Intervention does not reduce the risk of cancer 
Uncertainty over placement and significance of excision margins  
Risk of PMD recurrence 
No ability to predict clinical behaviour 
Poor functional outcome following treatment of widespread lesions 
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TABLE 3: ADVANTAGES OF PATIENT FOLLOW-UP AND SURVEILLANCE STRATEGIES  
POST- PMD TREATMENT  
 
 
Assess efficacy of treatment intervention 
Recognise treatment complications 
Early identification of recurrent or further PMD disease 
Early identification of cancer development 
Optimal timing and coordination of further treatment intervention 
Opportunities to modify patient risk factor behaviour 
Effective assessment of long-term patient risk 
Improve understanding of PMD natural history 
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TABLE 4: PMD MANAGEMENT GOALS AND TREATMENT EFFICACY  
 
 
  Treatment Modality  
Management Goals Observation Medical 
Therapy 
Laser 
Surgery 
References 
Accurate Diagnosis No No Yes 22, 23, 24, 25, 26, 27, 28, 29 
Prediction of Clinical Behaviour No No Possible 4, 7, 8, 30 
Early Recognition of Malignancy No No Yes 8, 23, 24, 25, 31, 32 
Removal of Dysplastic Mucosa No No Yes 4, 5, 6, 7, 8, 30, 33, 34 
Prevention of Further Disease  No No Possible 8, 35, 36, 37, 38, 39, 40, 41, 42 
Prevent Malignant Transformation No No Possible 3, 4, 5, 6, 7, 8, 13, 34, 43, 44 
Patient Acceptability and Minimal  
Morbidity 
No No Yes 4, 5, 6, 45, 46 
Cost-Effective ? ? Yes 5, 44 
 
 
 
 
 
 
 
 
